Skip to main content
SpringerLink
Log in

Human Polyomavirus (HPyV) and Organ Transplantation

  • Chapter
  • First Online:
Kidney Transplantation

Abstract

Human polyomaviruses are ubiquitous in the general population. In immune competent individuals, primary infection is usually asymptomatic, with lifelong viral persistence without serious clinical manifestations. Host immunological perturbations are associated with reactivation of these latent viruses and can result in a wide range of clinical presentations. For example, reemergence of this disease during the past two decades has been attributed to the use of potent maintenance immunosuppression (IS) therapy. Though recipients of kidney transplants are at increased risk of developing PyV reactivation compared to other solid organ transplants despite the use of similar types of IS therapy, this paradox remains poorly understood. The most common polyomaviral disease in recipients of kidney transplants is reactivation of BKPyV, leading to asymptomatic viruria in 30–50 % and viremia (20–25 %). Progression in viremia results in end organ damage, such as ureteral ulceration and ureteral stenosis; allograft nephropathy with special histological characteristics (PyVaN) develops in nearly 5–10 % of recipients, and graft failure develops in 45–70 % of patients with PyVAN. Nonrenal manifestations include skin lesions including skin rash (trichodysplasia spinulosa-associated skin disease due to TSPyV) and skin cancers (Merkel cell carcinoma), progressive multifocal leukoencephalopathy (PML) and rarely fatal vasculopathic illness, bladder cancer, and hemophagocytic syndrome. Increased net immunosuppression may be one of the factors that impair the immune effector mechanisms that allow polyomaviral replication. Thus interventions that can restore polyoma-specific immunity can abrogate viral replication. Based on this contemporary notion, reduction in maintenance IS therapy is an effective first-line therapy that has been shown to ameliorate viral load but may not be enough to result in sustained viral response. However, early detection of viremia with prospective monitoring by quantitative polymerase chain reaction has been defined as preemptive diagnosis. It is recommended that viremia should be monitored at frequent intervals during the first year of transplant. If viremia is persistent on more than two occasions, it should be treated with careful and prudent reduction in the intensity of baseline IS therapy. Currently there are no antipolyomaviral agents of proven efficacy and safety. Polyomaviral-directed active immunotherapy holds promise in the management of different clinical syndromes associated with polyomaviral reactivation in immunocompromised host.

This chapter will discuss recent advances in polyomaviral diseases, presentation of these unusual polyomaviral-associated end organ diseases, current treatment strategies, and their pitfalls.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol. 2003;71(1):115–23.

    PubMed  Google Scholar 

  2. Tremolada S. Mutations in the external loops of BK virus VP1 and urine viral load in renal transplant recipients. J Cell Physiol. 2010;222:195–9.

    PubMed Central  PubMed  CAS  Google Scholar 

  3. Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet. 1971;1(7712):1253–7.

    PubMed  CAS  Google Scholar 

  4. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1(7712):1257–60.

    PubMed  CAS  Google Scholar 

  5. Taguchi F, Kajioka J, Miyamura T. Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol. 1982;26(11):1057–64.

    PubMed  CAS  Google Scholar 

  6. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096–100.

    PubMed Central  PubMed  CAS  Google Scholar 

  7. van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gorbalenya AE, Feltkamp MC. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromised patient. PLoS Pathog. 2010;6(7):e1001024.

    PubMed Central  PubMed  Google Scholar 

  8. Allander T, Andreasson K, Gupta S, Bjerkner A, Bogdanovic G, Persson MA, et al. Identification of a third human polyomavirus. J Virol. 2007;81(8):4130–6.

    PubMed Central  PubMed  CAS  Google Scholar 

  9. Gaynor AM, Nissen MD, Whiley DM, Mackay IM, Lambert SB, Wu G, et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog. 2007;3(5):e64.

    PubMed Central  PubMed  Google Scholar 

  10. Payungporn S, Chieochansin T, Thongmee C, Samransamruajkit R, Theamboolers A, Poovorawan Y. Prevalence and molecular characterization of WU/KI polyomaviruses isolated from pediatric patients with respiratory disease in Thailand. Virus Res. 2008;135(2):230–6.

    PubMed  CAS  Google Scholar 

  11. Babakir-Mina M, Ciccozzi M, Perno CF, Ciotti M. The novel KI, WU, MC polyomaviruses: possible human pathogens? New Microbiol. 2011;34(1):1–8.

    PubMed  Google Scholar 

  12. Ming F, Eisenthal R, Whish WJ, Hubble J. The kinetics of affinity-mediated cell-surface attachment. Enzyme Microb Technol. 2000;26(2–4):216–21.

    PubMed  CAS  Google Scholar 

  13. Egli A. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis. 2009;199: 837–46.

    PubMed  CAS  Google Scholar 

  14. Zhong S. Age-related urinary excretion of BK polyomavirus by nonimmunocompromised individuals. J Clin Microbiol. 2007;45: 193–8.

    PubMed Central  PubMed  CAS  Google Scholar 

  15. Sundsfjord A, Osei A, Rosenqvist H. BK and JC viruses in patients with systemic lupus erythematosus: prevalent and persistent BK viruria, sequence stability of the viral regulatory regions, and nondetectable viremia. J Infect Dis. 1999;180:1–9.

    PubMed  CAS  Google Scholar 

  16. Bollag B, Chuke WF, Frisque RJ. Hybrid genomes of the polyomaviruses JC virus, BK virus, and simian virus 40: identification of sequences important for efficient transformation. J Virol. 1989;63:863–72.

    PubMed Central  PubMed  CAS  Google Scholar 

  17. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol. 2001;3(5):473–83.

    PubMed  CAS  Google Scholar 

  18. Pelkmans L, Puntener D, Helenius A. Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science. 2002;296(5567):535–9.

    PubMed  CAS  Google Scholar 

  19. Pho MT, Ashok A, Atwood WJ. JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol. 2000;74(5):2288–92.

    PubMed Central  PubMed  CAS  Google Scholar 

  20. Polo C, Perez JL, Mielnichuck A, Fedele CG, Niubo J, Tenorio A. Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect. 2004;10(7):640–4.

    PubMed  CAS  Google Scholar 

  21. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses. 2011;3(6):920–40.

    PubMed Central  PubMed  CAS  Google Scholar 

  22. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–20.

    PubMed  CAS  Google Scholar 

  23. Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol. 2008;8(12):911–22.

    PubMed  CAS  Google Scholar 

  24. Trinchieri G. Type I, interferon: friend or foe? J Exp Med. 2010;207(10):2053–63.

    PubMed Central  PubMed  CAS  Google Scholar 

  25. Ribeiro A, Wornle M, Motamedi N, Anders HJ, Grone EF, Nitschko H, et al. Activation of innate immune defense mechanisms contributes to polyomavirus BK-associated nephropathy. Kidney Int. 2012;81(1):100–11.

    PubMed  CAS  Google Scholar 

  26. Abend JR, Low JA, Imperiale MJ. Global effects of BKV infection on gene expression in human primary kidney epithelial cells. Virology. 2010;397:73–9.

    PubMed Central  PubMed  CAS  Google Scholar 

  27. Heutinck KM, Rowshani AT, Kassies J, Claessen N, van Donselaar-van der Pant KA, Bemelman FJ, et al. Viral double-stranded RNA sensors induce antiviral, pro-inflammatory, and pro-apoptotic responses in human renal tubular epithelial cells. Kidney Int. 2012;82(6):664–75.

    PubMed  CAS  Google Scholar 

  28. Hirsch HH, Knowles W, Dickenmann M. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347:488–96.

    PubMed  Google Scholar 

  29. Hirsch HH, Steiger J, Polyomavirus BK. Lancet Infect Dis. 2003;3(10):611–23.

    PubMed  Google Scholar 

  30. Reploeg MD, Storch GA, Clifford DB. Bk virus: a clinical review. Clin Infect Dis. 2001;33(2):191–202.

    PubMed  CAS  Google Scholar 

  31. Chakera A. Detection of polyomavirus BK reactivation after renal transplantation using an intensive decoy cell surveillance program is cost-effective. Transplantation. 2011;92:1018–23.

    PubMed  Google Scholar 

  32. Viscount HB. Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. Transplantation. 2007;84:340–5.

    PubMed  CAS  Google Scholar 

  33. Nickeleit V, True K, Detwiler R, Kozlowski T, Singh H. Risk assessment for polyomavirus nephropathy using urine cytology and the detection of decoy cells: cheap and efficient. Transplantation. 2012;94(7):e42–4.

    PubMed  Google Scholar 

  34. Nickeleit V, Klimkait T, Binet IF. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med. 2000;342:1309–15.

    PubMed  CAS  Google Scholar 

  35. Bressollette-Bodin C. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant. 2005;5:1926–33.

    PubMed  CAS  Google Scholar 

  36. Nickeleit V. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant. 2000;15:324–32.

    PubMed  CAS  Google Scholar 

  37. Boldorini R. Genomic mutations of viral protein 1 and BK virus nephropathy in kidney transplant recipients. J Med Virol. 2009;81:1385–93.

    PubMed  CAS  Google Scholar 

  38. Drachenberg CB. Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. Hum Pathol. 1999;30:970–7.

    PubMed  CAS  Google Scholar 

  39. Ding R, Medeiros M, Dadhania D. Noninvasive diagnosis of BK virus nephritis by measurement of messenger RNA for BK virus VP1 in urine. Transplantation. 2002;74:987–94.

    PubMed  CAS  Google Scholar 

  40. Singh HK. Presence of urinary Haufen accurately predicts polyomavirus nephropathy. J Am Soc Nephrol. 2009;20:416–27.

    PubMed Central  PubMed  CAS  Google Scholar 

  41. Memon IA, Parikh BA, Gaudreault-Keener M, Skelton R, Storch GA, Brennan DC. Progression from sustained BK viruria to sustained BK viremia with immunosuppression reduction is not associated with changes in the noncoding control region of the BK virus genome. J Transplant. 2012;2012:761283.

    PubMed Central  PubMed  Google Scholar 

  42. Carr MJ, McCormack GP, Mutton KJ, Crowley B. Unique BK virus non-coding control region (NCCR) variants in hematopoietic stem cell transplant recipients with and without hemorrhagic cystitis. J Med Virol. 2006;78(4):485–93.

    PubMed  CAS  Google Scholar 

  43. Anzivino E, Bellizzi A, Mitterhofer AP, Tinti F, Barile M, Colosimo MT, et al. Early monitoring of the human polyomavirus BK replication and sequencing analysis in a cohort of adult kidney transplant patients treated with basiliximab. Virol J. 2011;8:407.

    PubMed Central  PubMed  CAS  Google Scholar 

  44. Binet I. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation. 1999;67:918–22.

    PubMed  CAS  Google Scholar 

  45. Brennan DC. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005;5:582–94.

    PubMed  CAS  Google Scholar 

  46. Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant. 2013;13(1):136–45.

    PubMed Central  PubMed  CAS  Google Scholar 

  47. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364(20):1909–19.

    PubMed  CAS  Google Scholar 

  48. Ramos E, Drachenberg CB, Papadimitriou JC. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol. 2002;13:2145–51.

    PubMed  Google Scholar 

  49. Randhawa PS, Finkelstein S, Scantlebury V. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation. 1999;67:103–9.

    PubMed  CAS  Google Scholar 

  50. Randhawa P, Shapiro R, Vats A. Quantitation of DNA of polyomaviruses BK and JC in human kidneys. J Infect Dis. 2005;192(3): 504–9.

    PubMed  CAS  Google Scholar 

  51. Drachenberg CB. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant. 2004;4:2082–92.

    PubMed  Google Scholar 

  52. Gaber LW, Egidi MF, Stratta RJ, Lo A, Moore LW, Gaber AO. Clinical utility of histological features of polyomavirus allograft nephropathy. Transplantation. 2006;82(2):196–204.

    PubMed  Google Scholar 

  53. Hirsch HH, Randhawa P. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:179–88.

    PubMed  CAS  Google Scholar 

  54. Nickeleit V. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. J Am Soc Nephrol. 1999;10:1080–9.

    PubMed  CAS  Google Scholar 

  55. Wang Z, Portier BP, Hu B, Chiesa-Vottero A, Myles J, Procop GW, et al. Diagnosis of BK viral nephropathy in the renal allograft biopsy: role of fluorescence in situ hybridization. J Mol Diagn. 2012;14(5):494–500.

    PubMed  Google Scholar 

  56. Randhawa PS, Demetris AJ. Nephropathy due to polyomavirus type BK. N Engl J Med. 2000;342(18):1361–3.

    PubMed  CAS  Google Scholar 

  57. Hirsh HH, Randhawa P. BK virus in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S136–46.

    Google Scholar 

  58. Masutani K, Shapiro R, Basu A, Tan H, Wijkstrom M, Randhawa P. The Banff 2009 working proposal for polyomavirus nephropathy: a critical evaluation of its utility as a determinant of clinical outcome. Am J Transplant. 2012;12(4):907–18.

    PubMed Central  PubMed  CAS  Google Scholar 

  59. Celik B, Shapiro R, Vats A, Randhawa PS. Polyomavirus allograft nephropathy: sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression. Am J Transplant. 2003;3(11):1378–82.

    PubMed  Google Scholar 

  60. Ahuja M, Cohen EP, Dayer AM. Polyoma virus infection after renal transplantation. Use of immunostaining as a guide to diagnosis. Transplantation. 2001;71:896–9.

    PubMed  CAS  Google Scholar 

  61. Randhawa P, Shapiro R. Conceptual problems in the diagnosis and therapy of acute rejection in patients with polyomavirus nephropathy. Am J Transplant. 2004;4(5):840.

    PubMed  Google Scholar 

  62. Drachenberg CB, Hirsch HH, Papadimitriou JC, Gosert R, Wali RK, Munivenkatappa R, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation. 2007;84(3):323–30.

    PubMed  Google Scholar 

  63. Schwarz A, Linnenweber-Held S, Heim A, Brocker V, Rieck D, Framke T, et al. Factors influencing viral clearing and renal function during polyomavirus BK-associated nephropathy after renal transplantation. Transplantation. 2012;94(4):396–402.

    PubMed  CAS  Google Scholar 

  64. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int. 2006;69(4):655–62.

    PubMed  CAS  Google Scholar 

  65. Saad ER. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation. 2008;85:850–4.

    PubMed  CAS  Google Scholar 

  66. Sood P, Senanayake S, Sujeet K, Medipalli R, Zhu YR, Johnson CP, et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. Transplantation. 2012;94(8):814–21.

    PubMed  CAS  Google Scholar 

  67. Geetha D, Tong BC, Racusen L, Markowitz JS, Westra WH. Bladder carcinoma in a transplant recipient: evidence to implicate the BK human polyomavirus as a causal transforming agent. Transplantation. 2002;73(12):1933–6.

    PubMed  Google Scholar 

  68. Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation. 2009;87:621–30.

    PubMed  Google Scholar 

  69. Ginevri F. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant. 2007;7:2727–35.

    PubMed  CAS  Google Scholar 

  70. Geetha D, Parkhie S, Nadkarni GN, He C, Shafi T. Polyomavirus-associated nephropathy: a comparison of 2 different strategies for immunosuppression reduction. Medicine (Baltimore). 2011;90(5): 296–302.

    CAS  Google Scholar 

  71. Sanchez Fructuoso AI, Calvo N, Perez-Flores I, Valero R, Rodriguez-Sanchez B, García de Viedma D, et al. Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients. Transpl Infect Dis. 2011;13(6):584–91.

    PubMed  CAS  Google Scholar 

  72. Wali RK, Drachenberg C, Hirsch HH, Papadimitriou J, Nahar A, Mohanlal V, et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation. 2004;78(7):1069–73.

    PubMed  CAS  Google Scholar 

  73. Bernhoff E. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol. 2010;84:2150–6.

    PubMed Central  PubMed  CAS  Google Scholar 

  74. Williams JW, Javaid B, Kadambi PV. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med. 2005;352:1157–8.

    PubMed  CAS  Google Scholar 

  75. Canivet C. Polyoma BK, virus-associated nephropathy in kidney-transplant patients: effects of leflunomide on T-cell functions and disease outcome. Int Immunopharmacol. 2009;9:1131–6.

    PubMed  CAS  Google Scholar 

  76. Faguar S. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int. 2007;20: 962–9.

    Google Scholar 

  77. Krisl JC, Taber DJ, Pilch N, Chavin K, Bratton C, Thomas B, et al. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. Clin J Am Soc Nephrol. 2012;7(6):1003–9.

    PubMed  CAS  Google Scholar 

  78. Wu JK, Harris MT. Use of leflunomide in the treatment of polyomavirus BK-associated nephropathy. Ann Pharmacother. 2008;42(11):1679–85.

    PubMed  CAS  Google Scholar 

  79. Leca N. Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. Clin J Am Soc Nephrol. 2008;3:829–35.

    PubMed Central  PubMed  CAS  Google Scholar 

  80. Kadambi PV, Josephson MA, Williams J. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant. 2003;3:186–91.

    PubMed  Google Scholar 

  81. Hua DK, Howard K, Craig JC, Chapman JR, Wong G. Cost-effectiveness of cidofovir treatment of polyomavirus nephropathy in kidney transplant recipients. Transplantation. 2012;93(2): 188–94.

    PubMed  CAS  Google Scholar 

  82. Araya CE, Lew JF, Fennell RS, Neiberger RE, Dharnidharja VR. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr Transplant. 2008;12: 790–5.

    PubMed  CAS  Google Scholar 

  83. Kuypers DR. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant. 2005;5:1997–2004.

    PubMed  CAS  Google Scholar 

  84. Lamoth F, Pascual M, Erard V, Venetz JP, Nseir G, Meylan P. Low-dose cidofovir for the treatment of polyomavirus-associated nephropathy: two case reports and review of the literature. Antivir Ther. 2008;13(8):1001–9.

    PubMed  CAS  Google Scholar 

  85. Hakeem A, Sharma H, Sharma A. Cidofovir may be deleterious in BK virus-associated nephropathy. Transplantation. 2011;91(2): e11–2.

    PubMed  Google Scholar 

  86. Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH. Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antiviral Res. 2011;92(1): 115–23.

    PubMed  CAS  Google Scholar 

  87. Gabardi S. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol. 2010;5:1298–304.

    PubMed Central  PubMed  CAS  Google Scholar 

  88. Wojciechowski D, Chanda R, Chandran S, Lee B, Webber A, Macaraig M, et al. Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation. 2012;94(11):1117–23.

    PubMed  CAS  Google Scholar 

  89. Randhawa PS. Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin Infect Dis. 2005;41:1366–7.

    PubMed  Google Scholar 

  90. Anyaegbu EI, Almond PS, Milligan T, Allen WR, Gharaybeh S, Al-Akash SI. Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients. Pediatr Transplant. 2012;16(1):E19–24.

    PubMed  CAS  Google Scholar 

  91. Dalianis T. Immunotherapy for polyomaviruses: opportunities and challenges. Immunotherapy. 2012;4(6):617–28.

    PubMed  CAS  Google Scholar 

  92. Randhawa PS, Schonder K, Shapiro R, Farasati N, Huang Y. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation. 2010;89:1462–5.

    PubMed Central  PubMed  CAS  Google Scholar 

  93. Sener A. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation. 2006;81:117–20.

    PubMed  CAS  Google Scholar 

  94. Maggiore U, Medici MC, Vaglio A, Buzio C. Increased viral load after intravenous immunoglobulin therapy for BK virus-associated nephropathy. Transpl Infect Dis. 2010;12(5):470–2.

    PubMed  CAS  Google Scholar 

  95. Kuypers DR. Management of polyomavirus-associated nephropathy in renal transplant recipients. Nat Rev Nephrol. 2012;8(7): 390–402.

    PubMed  CAS  Google Scholar 

  96. Johnston O. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation. 2010;89: 1057–70.

    PubMed  Google Scholar 

  97. Trydzenskaya H, Sattler A, Muller K, Schachtner T, Dang-Heine C, Friedrich P, et al. Novel approach for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immunity. Transplantation. 2011;92(11):1269–77.

    PubMed  CAS  Google Scholar 

  98. Blyth E, Clancy L, Simms R, Gaundar S, O’Connell P, Micklethwaite K, et al. BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses. Transplantation. 2011;92(10): 1077–84.

    PubMed  CAS  Google Scholar 

  99. Gralla J, Huskey J, Wiseman AC. Trends in immune function assay (ImmuKnow; Cylex) results in the first year post-transplant and relationship to BK virus infection. Nephrol Dial Transplant. 2012;27(6):2565–70.

    PubMed  CAS  Google Scholar 

  100. Helantera I, Koskinen P. Association of immune cell function assay with protocol biopsy findings and viral infections in well matched kidney transplant recipients. Clin Nephrol. 2010;74(2): 123–31.

    PubMed  CAS  Google Scholar 

  101. Batal I. Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol. 2008;129:587–91.

    PubMed  CAS  Google Scholar 

  102. Mannon RB, Hoffmann SC, Kampen RL. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant. 2005;5:2883–93.

    PubMed  CAS  Google Scholar 

  103. Masutani K, Shapiro R, Basu A, Tan H, Ninomiya T, Randhawa P. Putative episodes of T-cell-mediated rejection in patients with sustained BK viruria but no viremia. Transplantation. 2012;94(1):43–9.

    PubMed Central  PubMed  Google Scholar 

  104. Kim SH, Ahn HJ, Kim YS, Kim SI, Kim HS, Jeong HJ. Urinary HLA-DR and CD54 expression—indicators for inflammatory activity in decoy cell shedding patients. Nephrol Dial Transplant. 2006;21(9):2601–6.

    PubMed  CAS  Google Scholar 

  105. Sadeghi M. Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation. 2009;88:1109–16.

    PubMed  CAS  Google Scholar 

  106. Kusne S, Vilchez RA, Zanwar P, Quiroz J, Mazur MJ, Heilman RL, et al. Polyomavirus JC urinary shedding in kidney and liver transplant recipients associated with reduced creatinine clearance. J Infect Dis. 2012;206(6):875–80.

    PubMed Central  PubMed  Google Scholar 

  107. Drachenberg CB, Papadimitriou JC, Mann D, Hirsch HH, Wali R, Ramos E. Negative impact of human leukocyte antigen matching in the outcome of polyomavirus nephropathy. Transplantation. 2005;80(2):276–8.

    PubMed  Google Scholar 

  108. Awadalla Y. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant. 2004;4:1691–6.

    PubMed  CAS  Google Scholar 

  109. Awadallah Y, Duquesnoy R, Randhawa P, Shapiro R. HLA susceptibility to BKV infection. Am J Transplant. 2006;6:640.

    PubMed  CAS  Google Scholar 

  110. Sharif A, Alachkar N, Bagnasco S, Geetha D, Gupta G, Womer K, et al. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7(8):1320–7.

    PubMed Central  PubMed  Google Scholar 

  111. Hammer MH. HLA type-independent method to monitor polyoma BK virus-specific CD4 and CD8 T-cell immunity. Am J Transplant. 2006;6:625–31.

    PubMed  CAS  Google Scholar 

  112. Geetha D, Sozio SM, Ghanta M, Josephson M, Shapiro R, Dadhania D, et al. Results of repeat renal transplantation after graft loss from BK virus nephropathy. Transplantation. 2011;92(7):781–6.

    PubMed  Google Scholar 

  113. Ramos E, Vincenti F, Lu WX. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation. 2004;77:131–3.

    PubMed  Google Scholar 

  114. Womer KL, Patton PR, Kaplan B. Aggressive post-transplant monitoring of more importance to successful outcome following re-transplantation for BK virus nephropathy than absence of pretransplant viremia. Transpl Int. 2008;21:1103–4.

    PubMed  Google Scholar 

  115. Mindlova M, Boucek P, Saudek F, Jedinakova T, Voska L, Honsova E, et al. Kidney retransplantation following graft loss to polyoma virus-associated nephropathy: an effective treatment option in simultaneous pancreas and kidney transplant recipients. Transpl Int. 2008;21(4):353–6.

    PubMed  Google Scholar 

  116. Hirsh HH, Ramos E. Retransplantation after polyomavirus-associated nephropathy: just do it? Am J Transplant. 2006;6:7–9.

    Google Scholar 

  117. Egli A, Helmersen DS, Taub K, Hirsch HH, Johnson A. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. Am J Transplant. 2010;10(10): 2324–30.

    PubMed  CAS  Google Scholar 

  118. Barton TD, Blumberg EA, Doyle A, Ahya VN, Ferrenberg JM, Brozena SC, et al. A prospective cross-sectional study of BK virus infection in non-renal solid organ transplant recipients with chronic renal dysfunction. Transpl Infect Dis. 2006;8(2):102–7.

    PubMed  CAS  Google Scholar 

  119. Munoz P. Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect Dis. 2005;41:1720–5.

    PubMed  Google Scholar 

  120. Razonable RR, Brown RA, Humar A, Covington E, Alecock E, Paya CV. A longitudinal molecular surveillance study of human polyomavirus viremia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis. 2005;192(8):1349–54.

    PubMed  CAS  Google Scholar 

  121. Salama M, Boudville N, Speers D, Jeffrey GP, Ferrari P. Decline in native kidney function in liver transplant recipients is not associated with BK virus infection. Liver Transpl. 2008;14(12): 1787–92.

    PubMed  Google Scholar 

  122. Haririan A, Hamze O, Drachenberg CB, Ramos E, Weir MR, Klassen DK. Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. Transplantation. 2003;75(8): 1186–90.

    PubMed  Google Scholar 

  123. Vilchez RA, Kusne S. Molecular and clinical perspectives of polyomaviruses: emerging evidence of importance in non-kidney transplant populations. Liver Transpl. 2006;12(10):1457–63.

    PubMed  Google Scholar 

  124. Doucette KE, Pang XL, Jackson K, Burton I, Carbonneau M, Cockfield S, et al. Prospective monitoring of BK polyomavirus infection early posttransplantation in nonrenal solid organ transplant recipients. Transplantation. 2008;85(12):1733–6.

    PubMed  Google Scholar 

  125. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int. 2005;17(11):658–65.

    PubMed  Google Scholar 

  126. Verhelst X, Vanhooren G, Vanopdenbosch L, Casselman J, Laleman W, Pirenne J, et al. Progressive multifocal leukoencephalopathy in liver transplant recipients: a case report and review of the literature. Transpl Int. 2011;24(4):e30–4.

    PubMed  Google Scholar 

  127. Bellizzi A, Nardis C, Anzivino E, Rodio D, Fioriti D, Mischitelli M, et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol. 2012;18(1):1–11.

    PubMed  CAS  Google Scholar 

  128. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol. 2009;10(8):816–24.

    PubMed  CAS  Google Scholar 

  129. Elaba Z, Hughey L, Isayeva T, Weeks B, Solovan C, Solovastru L, et al. Ultrastructural and molecular confirmation of the trichodysplasia spinulosa-associated polyomavirus in biopsies of patients with trichodysplasia spinulosa. J Cutan Pathol. 2012;39(11):1004–9.

    PubMed  Google Scholar 

  130. Sihto H, Kukko H, Koljonen V, Sankila R, Bohling T, Joensuu H. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst. 2009;101(13): 938–45.

    PubMed  CAS  Google Scholar 

  131. Esposito L, Hirsch H, Basse G, Fillola G, Kamar N, Rostaing L. BK virus-related hemophagocytic syndrome in a renal transplant patient. Transplantation. 2007;83(3):365.

    PubMed  Google Scholar 

  132. Karras A, Thervet E, Legendre C. Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation. 2004;77(2):238–43.

    PubMed  Google Scholar 

  133. Bratt G, Hammarin AL, Grandien M, Hedquist BG, Nennesmo I, Sundelin B, et al. BK virus as the cause of meningoencephalitis, retinitis and nephritis in a patient with AIDS. AIDS. 1999;13(9): 1071–5.

    PubMed  CAS  Google Scholar 

  134. Hedquist BG, Bratt G, Hammarin AL, Grandien M, Nennesmo I, Sundelin B, et al. Identification of BK virus in a patient with acquired immune deficiency syndrome and bilateral atypical retinitis. Ophthalmology. 1999;106(1):129–32.

    PubMed  CAS  Google Scholar 

  135. Sandler ES, Aquino VM, Goss-Shohet E, Hinrichs S, Krisher K. BK papova virus pneumonia following hematopoietic stem cell transplantation. Bone Marrow Transplant. 1997;20(2):163–5.

    PubMed  CAS  Google Scholar 

  136. Petrogiannis-Haliotis T, Sakoulas G, Kirby J. BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med. 2001;345:1250–5.

    PubMed  CAS  Google Scholar 

  137. Sencer SF, Haake RJ, Weisdorf DJ. Hemorrhagic cystitis after bone marrow transplantation. Risk factors and complications. Transplantation. 1993;56(4):875–9.

    PubMed  CAS  Google Scholar 

  138. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309(22):1347–53.

    PubMed  CAS  Google Scholar 

  139. Silva LP, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica. 2010;95(7):1183–90.

    Google Scholar 

  140. Leung AY, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood. 2001;98(6): 1971–8.

    PubMed  CAS  Google Scholar 

  141. Dalianis T, Ljungman P. Full myeloablative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoietic stem cell transplanted patients. Anticancer Res. 2011;31(3):939–44.

    PubMed  Google Scholar 

  142. Giraud G, Bogdanovic G, Priftakis P, Remberger M, Svahn BM, Barkholt L, et al. The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica. 2006;91(3):401–4.

    PubMed  Google Scholar 

  143. Giraud G, Priftakis P, Bogdanovic G, Remberger M, Dubrulle M, Hau A, et al. BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. Bone Marrow Transplant. 2008;41(8):737–42.

    PubMed  CAS  Google Scholar 

  144. Leung AY. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40:528–37.

    PubMed  CAS  Google Scholar 

  145. Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, et al. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011;17(8):1176–81.

    PubMed  CAS  Google Scholar 

  146. Bridges B, Donegan S, Badros A. Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation. Am J Hematol. 2006;81(7):535–7.

    PubMed  Google Scholar 

  147. Erard V, Kim HW, Corey L, Limaye A, Huang ML, Myerson D, et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood. 2005;106(3):1130–2.

    PubMed Central  PubMed  CAS  Google Scholar 

  148. Leung AY, Yuen KY, Kwong YL. Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm. Bone Marrow Transplant. 2005;36(11):929–37.

    PubMed  CAS  Google Scholar 

  149. Cesaro S, Hirsch HH, Faraci M, Owoc-Lempach J, Beltrame A, Tendas A, et al. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis. 2009;49(2):233–40.

    PubMed  CAS  Google Scholar 

  150. Savona MR, Newton D, Frame D, Levine JE, Mineishi S, Kaul DR. Low-dose cidofovir treatment of BK virus-associated hemorrhagic cystitis in recipients of hematopoietic stem cell transplant. Bone Marrow Transplant. 2007;39(12):783–7.

    PubMed  CAS  Google Scholar 

  151. Alexiev BA, Randhawa P, Vazquez ME, Zeng G, Luo C, Ramos E, et al. BK virus-associated urinary bladder carcinoma in transplant recipients: report of 2 cases, review of the literature, and proposed pathogenetic model. Hum Pathol. 2013;44(5):908–17.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Balamand University, Faculty of Medicine, Beirut, Lebanon

    Sabine Karam M.D.

  2. University of Maryland School of Medicine, Baltimore, MD, USA

    Ravinder Wali M.D.

  3. Inova Health System, 3300 Gallows Road, Falls Church, VA, 22042-9937, USA

    Ravinder Wali M.D.

Authors
  1. Sabine Karam M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ravinder Wali M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ravinder Wali M.D. .

Editor information

Editors and Affiliations

  1. Department of Nephrology, University of Maryland, Baltimore, Maryland, USA

    Matthew R. Weir

  2. Department of Medicine, Section of Nephrology, University of Illinois, Berwyn, Illinois, USA

    Edgar V. Lerma

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Karam, S., Wali, R. (2014). Human Polyomavirus (HPyV) and Organ Transplantation. In: Weir, M., Lerma, E. (eds) Kidney Transplantation. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0342-9_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0342-9_28

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0341-2

  • Online ISBN: 978-1-4939-0342-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation